ScreenerHero

MCRB Seres Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · serestherapeutics.com
2.720USD-6.21%Mkt Cap: 27.32M $P/E: —

Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhanc…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap27.32M USD
Enterprise Value69.88M USD
Revenue (TTM)1.88M USD
Gross Profit-5.75M USD
Net Income (TTM)5.70M USD
Revenue/Share0.20 USD
Last Price2.720 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees66
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.59
PEG—
EV/EBITDA-0.93
EV/Revenue37.11
P/S15.47
P/B0.83
EPS (TTM)-2.50
EPS (Forward)-4.95
52W Range
2.7000% of range29.98
52W High29.98 USD
52W Low2.700 USD
Profitability
Gross Margin-729.40%
Oper. Margin-2101.36%
EBITDA Margin0.00%
Profit Margin721.93%
ROE12.88%
ROA4.12%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF1.12M USD
CapEx (TTM)252.00K USD
FCF Margin-3430.74%
FCF Yield-236.44%
Net Debt41.05M USD
Net Debt/EBITDA-0.55
Balance Sheet
Debt/Equity1.88
Current Ratio2.11
Quick Ratio2.04
Book Value/Sh3.51 USD
Cash/Share1.57 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateApr 22, 2025
Analyst Consensus
Rating—
Target (Mean)17.00 USD
Upside (mean)+525.0%
Target Range12.00 USD – 22.00 USD
12.00+525.0% to mean22.00
# Analysts2
Ownership
Shares Out.10.04M
Float8.73M
Insiders11.49%
Institutions22.93%
Short Interest
Short Ratio5.3d
Short % Float3.88%
Short % Out.3.00%
Shares Short301.34K
Short (prev mo.)367.86K
Technical
SMA 504.542 (-40.1%)
SMA 2008.336 (-67.4%)
Beta0.31
S&P 52W Chg16.45%
Avg Vol (30d)66.81K
Avg Vol (10d)82.51K
Technical Indicators
RSI (14)19.6
MACD-0.5802
MACD Signal-0.4850
MACD Hist.-0.0953
BB Upper5.663 USD
BB Middle3.900 USD
BB Lower2.136 USD
BB Width90.47%
ATR (14)0.3215 USD
Vol Ratio (20d)0.89x